KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.

Translational lung cancer research（2022）

引用 2|浏览13

暂无评分

摘要

This work provides evidence that mutation in advanced NSCLC may be served as a potential predictive biomarker for immunotherapeutic efficacy.

查看译文

关键词

KRAS mutation,Non-small cell lung carcinoma (NSCLC),PD-L1 expression,biomarker,tumor mutational burden (TMB)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要